News headlines about Novo Nordisk A/S (NYSE:NVO) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.4022014214342 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

Shares of Novo Nordisk A/S stock opened at $47.46 on Monday. Novo Nordisk A/S has a 1 year low of $44.28 and a 1 year high of $58.37. The stock has a market cap of $114.53 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 2.52 and a beta of 0.66.

The firm also recently announced a special dividend, which will be paid on Tuesday, August 28th. Shareholders of record on Monday, August 20th will be issued a dividend of $0.4669 per share. This represents a yield of 1.72%. The ex-dividend date is Friday, August 17th. Novo Nordisk A/S’s payout ratio is 38.89%.

Several research analysts have issued reports on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $64.00.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Featured Article: Outstanding Shares and The Effect on Share Price

Insider Buying and Selling by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with's FREE daily email newsletter.